Premium
The effect of atorvastatin on serum lipoproteins in acromegaly
Author(s) -
Mishra Manoj,
Durrington Paul,
Mackness Mike,
Siddals Kirk W.,
Kaushal Kalpana,
Davies Rob,
Gibson Martin,
Ray David W.
Publication year - 2005
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.2005.02273.x
Subject(s) - medicine , endocrinology , atorvastatin , apolipoprotein b , acromegaly , very low density lipoprotein , placebo , lipoprotein , cholesterol , triglyceride , cholesterylester transfer protein , hormone , growth hormone , alternative medicine , pathology
Objective Acromegaly is associated with long‐term adverse effects on cardiovascular mortality and morbidity. Reducing growth hormone secretion improves well‐being and symptoms, but may not significantly improve the lipoprotein profile. An additional approach to cardiovascular risk reduction in acromegaly may therefore be to target lipoprotein metabolism directly. In this study we investigated the effect of statin treatment. Design Double blind, placebo‐controlled, crossover study of the effects on circulating lipoproteins of atorvastatin 10 mg daily vs. placebo. Each treatment was given for 3 months in random order. Subjects Eleven patients with acromegaly. Measurements Lipids, lipoproteins, apolipoproteins, enzyme activity and calculated cardiovascular risk. Results Atorvastatin treatment compared to placebo resulted in a significant decrease in serum cholesterol (5·85 ± 1·04 mmol/l vs. 4·22 ± 0·69 mmol/l; mean ± SD; P < 0·001), low‐density lipoprotein (LDL) cholesterol (2·95 ± 1·07 mmol/l vs. 1·82 ± 0·92 mmol/l; P < 0·001), very low‐density lipoprotein (VLDL) cholesterol (0·31 (0·21–0·47) mmol vs. 0·23 (0·13–0·30) mmol/l median (interquartile range); P < 0·05), apolipoprotein B (111 ± 28 mg/dl vs. 80 ± 18 mg/dl; P < 0·001), and calculated coronary heart disease risk (6·8 (3·3–17·9) vs. 2·8 (1·5–5·7)% over next 10 years; P < 0·01). Serum triglyceride was 1·34 (1·06–1·71) mmol/l on placebo and 1·14 (0·88–1·48) mmol/l on atorvastatin (ns). HDL cholesterol, apolipoprotein A1 and Lp(a) concentrations and cholesteryl ester transfer protein and lecithin: cholesterol acyl transferase activities were also not significantly altered. Conclusion Atorvastatin treatment was safe, well tolerated and effective in improving the atherogenic lipoprotein profile in acromegaly.